Summary:
- Researchers at St. Jude Children's Research Hospital have identified the RNA-binding protein MBNL1 as a significant therapeutic target for treating high-risk B-cell acute lymphoblastic leukemia (B-ALL).
- The study demonstrates that MBNL1 plays a critical role in promoting leukemia cell survival by regulating alternative splicing, suggesting that inhibiting this protein could offer a novel strategy for treating chemotherapy-resistant childhood cancers.